Today, about half of all therapeutic drug approvals by the US Food and Drug Administration (FDA) are for biological drugs. That number is expected to rise to 75 percent by 2025. When these biologics come off patent, the gates will open for a flood of biosimilar drugs (biopharmaceutical generics) that are designed to be much […]
The post Critical Factors for Full Characterization of Biosimilars appeared first on Bitesize Bio.
No comments:
Post a Comment